EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TriSalus Life Sciences's enterprise value is $285.68 Mil.
TriSalus Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-58.48 Mil. Therefore, TriSalus Life Sciences's EV-to-EBITDA for today is -4.89.
The historical rank and industry rank for TriSalus Life Sciences's EV-to-EBITDA or its related term are showing as below:
TLSI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.97 Med: -3.68 Max: -0.61
Current: -4.89
During the past 3 years, the highest EV-to-EBITDA of TriSalus Life Sciences was -0.61. The lowest was -5.97. And the median was -3.68.
TLSI's EV-to-EBITDA is ranked worse than 100% of 483
companies
in the Medical Devices & Instruments industry
Industry Median: 16.47
vs TLSI: -4.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TriSalus Life Sciences's EV-to-EBITDA
For the Medical Devices subindustry, TriSalus Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's EV-to-EBITDA falls into.
TriSalus Life Sciences's current Enterprise Value is $285.68 Mil.
TriSalus Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (NAS:TLSI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
TriSalus Life Sciences's PE Ratio for today is calculated as:
TriSalus Life Sciences's share price for today is $9.83.
TriSalus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.492.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of TriSalus Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
TriSalus Life Sciences (TriSalus Life Sciences) Business Description
TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TLSI has been successfully added to your